Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Pufang Tan; Xiaogang Li; Jun Shen; Qi Feng

doi:10.3389/fphar.2020.574533

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Front Pharmacol. 2020 Sep 18:11:574533. doi: 10.3389/fphar.2020.574533. eCollection 2020.

Authors

Pufang Tan¹, Xiaogang Li¹, Jun Shen^{1

2}, Qi Feng³

Affiliations

¹ Division of Gastroenterology and Hepatology, Baoshan Branch, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
² Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China.
³ Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Abstract

Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.

Keywords: Crohn’s disease; fecal microbiota transplantation; inflammatory bowel disease; microbiome; ulcerative colitis.

Publication types

Review